Risk-benefit model for TTS events applied to the Johnson & Johnson vaccine.

(At the request of the Taskforce Vaccination - End of May 2021)

Together with the Federal Agency for Medicines and Health products (FAMHP) and the Taskforce Vaccination, KCE did a rapid adaption of the European Medicines Agency (EMA) risk-benefit model for thrombocytopenia syndrome (TTS) after vaccination for Vaxzevria™ to the Johnson & Johnson vaccine. We reused the EU estimates on hospitalisation, ICU and death, provided by EMA, for calculating the possible benefits of vaccination with the Johnson & Johnson vaccine. These possible benefits were then compared to the possible risk on thrombocytopenia syndrome (TTS) after vaccination with the Johnson & Johnson vaccine.

Download the document: Risk benefit in context for TTS events applied to the Johnson & Johnson vaccine
 

Contact
Karin Rondia (FR)
+32 (0)2 287 33 48
+32 (0)475 769 766
ANNUAL REPORT
Published on: 
2021/08/17